Diaceutics’ growth reflects the rise in diagnostic use in enabling therapies
April 13th, 2017
Since inception, Diaceutics has been involved in more than 200 drug launches and currently has a 60% share in the top 10 global markets. We currently count 26 out of the world’s top 30 pharmaceutical companies as clients and provide oversight, analysis and tracking of testing in 23 markets, every year helping 48,000 cancer patients access the personalized medicine that is right for them.
Our knowledge of diagnostic commercialization has allowed us to develop as a company in line with the increasing use of diagnostics and pharma’s understanding of the importance of testing. To ensure we support and guide our pharma clients we bring global experts from the laboratory, diagnostic and pharmaceutical industries into the team.
This team is set to increase considerably as we lead the way in integrating diagnostic testing into drug launch programmes. [php slug=GetLink param=”id=6300&title=Diaceutics has just announced 30 new jobs&useTitle=true”] which will see us grow to 100 people by end of 2018, reflecting the company’s growing international influence as we expand in key markets such as the US, EU, Asia and South America.
To help facilitate the growth in its business, Diaceutics recently strengthened its senior management team with the addition of three domain experts:
Dr. Juliesta E. Sylvester is a new managing director of data and analytics, and will be developing our analytics platform to generate actionable insights for partners and clients.
Dr. Peter Krein is a new managing director of client operations and will promote business growth through new strategic initiatives.
Dr. Merdol Ibrahim will lead the global Laboratory Implementation team, building peer relationships with laboratories and pharma clients to support the launch and long-term adoption of diagnostic biomarkers and associated technologies.
Peter Keeling, CEO, Diaceutics, said: “Testing is now at the heart of pharmaceutical companies’ ability to identify the right patients for their new therapies. We are uniquely positioned to provide the global testing perspective that allows this identification and treatment of patients who will benefit from specific and often life-saving drugs.”
With a market forecast to grow from $1.4bn today to $4bn by 2020, Diaceutics is set to transform an industry model by enabling pharmaceutical companies to accelerate their market penetration and achieve a better return on new therapies.